Press Releases

Latest News & Events

    Quick Facts

    Paradigm shifting immunotherapy For complex, unmet clinical need indications

    Paradigm shifting immunotherapy
    For complex, life-threatening indications without therapies

    Advanced clinical-stage pipeline with promising phase 2a results

    Advanced clinical-stage pipeline
    Promising results of PhIb (sepsis) and PhIIa (GvHD) studies, initiating Sepsis Phase IIb study

    Advanced clinical-stage pipeline with promising phase 2a results

    Multi-billion dollar
    underserved markets

    Sepsis | Solid Tumors, Covid-19,
    Bone-Marrow Transplantations

    Short regulatory approval pathway FDA & EU orphan designations; Specialized life-threatening regulation in Europe potentially enabling post-Phase II marketing approval

    Short regulatory approval pathway
    Specialized regulation in Europe potentially enabling post-Phase II marketing approval

    Strong leadership Previously founded and managed PROLOR Biotech, sold For $560M; Signed partnership with Pfizer, $295 Million down payment

    Strong leadership
    Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment

    Cash balance $30 Million invested; Expected cash balance of 2.5 Years at closing, Next clinical milestone within 12 months

    Cash balance
    ~$60 Million invested; Cash balance supporting multiple clinical milestone within 18-24 months

    SEC Filings

    Date Form Description Download

    Corporate Governance

    Charter of the Audit Committee of the Board of Directors download
    Charter of the Compensation Committee of the Board of Directors download
    Code of Business Conduct and Ethics download
    Disclosure Policy download
    Employee Complaint Procedures for Accounting and Auditing Matters download
    Insider Trading Policy download
    Download our company overview

    Find out more

    14 Einstein St. Nes-Ziona, Israel, 7403618
    T +972.2.6708072  |  F +972.2.6708070
    info@enlivex.com